CN1871009A - 作为抗癌剂的5－芳基嘧啶 - Google Patents

作为抗癌剂的5－芳基嘧啶 Download PDF

Info

Publication number
CN1871009A
CN1871009A CNA200480031581XA CN200480031581A CN1871009A CN 1871009 A CN1871009 A CN 1871009A CN A200480031581X A CNA200480031581X A CN A200480031581XA CN 200480031581 A CN200480031581 A CN 200480031581A CN 1871009 A CN1871009 A CN 1871009A
Authority
CN
China
Prior art keywords
chloro
pyrimidin
amine
pharmaceutically acceptable
trifluoroethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480031581XA
Other languages
English (en)
Chinese (zh)
Inventor
张楠
塞米拉米斯·埃拉尔-卡洛斯蒂安
阮泰协
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Publication of CN1871009A publication Critical patent/CN1871009A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA200480031581XA 2003-09-24 2004-09-17 作为抗癌剂的5－芳基嘧啶 Pending CN1871009A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24
US60/505,487 2003-09-24

Publications (1)

Publication Number Publication Date
CN1871009A true CN1871009A (zh) 2006-11-29

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480031581XA Pending CN1871009A (zh) 2003-09-24 2004-09-17 作为抗癌剂的5－芳基嘧啶

Country Status (24)

Country Link
US (1) US7524849B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663241B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007506746A (cg-RX-API-DMAC7.html)
KR (1) KR20060089215A (cg-RX-API-DMAC7.html)
CN (1) CN1871009A (cg-RX-API-DMAC7.html)
AR (1) AR045811A1 (cg-RX-API-DMAC7.html)
AT (1) ATE432077T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004275733A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414736A (cg-RX-API-DMAC7.html)
CA (1) CA2539235A1 (cg-RX-API-DMAC7.html)
CO (1) CO5690592A2 (cg-RX-API-DMAC7.html)
DE (1) DE602004021269D1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066457A (cg-RX-API-DMAC7.html)
GT (1) GT200400188A (cg-RX-API-DMAC7.html)
IL (1) IL174305A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003207A (cg-RX-API-DMAC7.html)
NO (1) NO20061319L (cg-RX-API-DMAC7.html)
PA (1) PA8613201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050470A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006107578A (cg-RX-API-DMAC7.html)
SA (1) SA04250303A (cg-RX-API-DMAC7.html)
TW (1) TW200512198A (cg-RX-API-DMAC7.html)
WO (1) WO2005030216A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602386B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585618A (zh) * 2019-11-01 2022-06-03 优迈特株式会社 含氟嘧啶化合物及其制造方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
JP2008543838A (ja) * 2005-06-13 2008-12-04 ワイス チューブリンインヒビターおよびその調製のためのプロセス
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
US20110201496A1 (en) * 2006-03-27 2011-08-18 Joachim Rheinheimer Substituted 5-Hetaryl-4-Aminopyrimidines
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
WO2008084081A2 (en) * 2007-01-11 2008-07-17 Basf Se 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
HUE064883T2 (hu) 2011-04-22 2024-04-28 Signal Pharm Llc Szubsztituált diaminokarboxamid- és diaminokarbonitril-pirimidinek, azok készítményei és azokkal történõ kezelési eljárások
WO2014047257A2 (en) 2012-09-19 2014-03-27 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
KR102606253B1 (ko) 2014-12-16 2023-11-27 시그날 파마소티칼 엘엘씨 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88096A (en) * 1869-03-23 t h a y e r
US69242A (en) * 1867-09-24 Calvin pepper
US61889A (en) * 1867-02-05 Improvement in animal teaps
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
EP1076053B1 (en) 1998-04-27 2006-11-29 Kumiai Chemical Industry Co., Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
US5986135A (en) 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
ES2246330T3 (es) 2000-06-13 2006-02-16 Basf Aktiengesellschaft 2-(cianoamino)pirimidinas 5-fenil-sustituidas fungicidas.
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
BR0207975A (pt) * 2001-03-15 2004-06-15 Basf Ag Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos
ES2242839T3 (es) 2001-04-20 2005-11-16 Ciba Specialty Chemicals Holding Inc. 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas.
US7465735B2 (en) 2001-11-19 2008-12-16 Basf Aktiengesellschaft 5-Phenypyrimidines their preparation compositions comprising them and their use
EP1504001B1 (de) 2002-02-21 2009-04-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
DE60314730T2 (de) 2002-03-15 2008-06-05 Ciba Specialty Chemicals Holding Inc. Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
WO2004048365A1 (en) 2002-11-21 2004-06-10 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585618A (zh) * 2019-11-01 2022-06-03 优迈特株式会社 含氟嘧啶化合物及其制造方法
US12371422B2 (en) 2019-11-01 2025-07-29 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound and manufacturing method for same

Also Published As

Publication number Publication date
AU2004275733A1 (en) 2005-04-07
SA04250303A (ar) 2005-12-03
WO2005030216A1 (en) 2005-04-07
AR045811A1 (es) 2005-11-16
NO20061319L (no) 2006-04-20
ZA200602386B (en) 2009-03-25
CA2539235A1 (en) 2005-04-07
US7524849B2 (en) 2009-04-28
EP1663241B1 (en) 2009-05-27
IL174305A0 (en) 2008-02-09
US20050075357A1 (en) 2005-04-07
ECSP066457A (es) 2006-09-18
PE20050470A1 (es) 2005-10-03
MXPA06003207A (es) 2006-06-23
TW200512198A (en) 2005-04-01
RU2006107578A (ru) 2007-10-27
GT200400188A (es) 2005-05-02
DE602004021269D1 (de) 2009-07-09
ATE432077T1 (de) 2009-06-15
CO5690592A2 (es) 2006-10-31
BRPI0414736A (pt) 2006-11-21
KR20060089215A (ko) 2006-08-08
EP1663241A1 (en) 2006-06-07
PA8613201A1 (es) 2005-11-25
JP2007506746A (ja) 2007-03-22

Similar Documents

Publication Publication Date Title
CN100351253C (zh) 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
CN1151155C (zh) 1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物
CN1871009A (zh) 作为抗癌剂的5－芳基嘧啶
CN1257891C (zh) 含氮五员环化合物
CN1198825C (zh) 8－苯基－6,9－二氢－[1,2,4]三唑并[3,4－i]嘌呤－5－酮衍生物
CN1890218A (zh) 微管蛋白抑制剂
CN1592624A (zh) 被取代的三唑并嘧啶类化合物作为抗癌药
HK1041260A1 (zh) 2-脲基噻唑衍生物及其製備方法和作為抗腫瘤劑的應用
HK1041483A1 (en) Bicyclic nitrogen heterocycles
CN1711264A (zh) 具有抗癌活性的嘧啶并[4,5－d]嘧啶衍生物
CN1553899A (zh) 抑制肝细胞生长因子受体自磷酸化的喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
CN1071164A (zh) 含氮杂环化合物
CN1649863A (zh) 具有cdk抑制活性的4－(咪唑－5－基)－2－(4－磺基苯胺基)嘧啶衍生物
CN1218471A (zh) 咔啉衍生物
CN101044137A (zh) 作为plk抑制剂的2,4－二（氨基苯基）嘧啶
CN1675214A (zh) 具有抗增殖活性的嘧啶并化合物
CN1753670A (zh) 新苯并咪唑和咪唑并吡啶衍生物及其作为药物的用途
CN1271349A (zh) 取代的喹唑啉衍生物及其作为酪氨酸激酶抑制剂的用途
HK1045687A1 (zh) 作為抗腫瘤劑的4，5，6，7-四氫吲唑衍生物
CN1542010A (zh) 吡咯并三嗪和嘧啶化合物
CN1503794A (zh) 作为抗癌剂的细胞周期蛋白依赖性激酶抑制剂
CN1867569A (zh) 作为抗癌剂的6－[(经取代的)苯基]三唑并嘧啶
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN1639133A (zh) 新抗菌化合物、其制备方法和含有它们的药物组合物
CN1571781A (zh) 4－咪唑啉－2－酮化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20061129

C20 Patent right or utility model deemed to be abandoned or is abandoned